Cardiff Oncology, Inc. (DE:XE7C)
NASDAQ:XE7C
XE7C Stock Chart & Stats
€1.56
-€0.37(-8.64%)
At close: 4:00 PM EST
€1.56
-€0.37(-8.64%)
Day’s Range― - ―
52-Week Range€1.13 - €3.76
Previous CloseN/A
Volume0.00
Average Volume (3M)267.00
Market Cap
€90.78M
Enterprise Value€122.00M
Total Cash (Recent Filing)€46.06M
Total Debt (Recent Filing)€646.00K
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Jul 30, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding68,369,896
10 Day Avg. Volume306
30 Day Avg. Volume267
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)4.14
Price to Sales (P/S)316.73
P/FCF Ratio-4.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.19Price Target Upside232.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.59
Revenue Forecast (FY)€206.26K
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And Registrational PathThe 72% objective response rate with PFS not yet reached and favorable safety materially de-risks onvansertib’s clinical profile. Dose selection and a successful end-of-Phase-2 regulator discussion support a clear Phase 3/registrational pathway, strengthening long-term commercial potential and partnership appeal.
Experienced Management AdditionsPermanent appointments of a CEO, CFO and COO with capital-markets and clinical development experience should improve execution, fundraising and regulatory navigation. Strong operational leadership increases the probability of timely Phase 3 delivery and efficient use of capital over the next several quarters.
Conservative Leverage On Balance SheetVery low absolute debt and minimal financial leverage reduce interest burden and insolvency risk. This conservative capital structure gives the company flexibility to pursue equity or partnership financing and lowers near-term financial distress risk while clinical programs progress.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow of roughly -$37M TTM requires ongoing external capital to fund trials and operations. Persistent burn increases dilution risk, constrains strategic optionality, and could delay or limit Phase 3 activities absent partnerships or committed financing.
Minimal Revenue And Large LossesWith virtually no commercial revenue and substantial operating losses, the company lacks earned cash inflows to fund development. Long-term sustainability depends on clinical success, partnering, or capital markets access, increasing vulnerability to clinical setbacks or market funding dislocations.
Material IP/license Dispute Over Lead AssetAn active legal dispute and a notice of license termination from the licensor create existential risk for onvansertib. Loss of license rights or protracted litigation could halt development, deter partners and investors, and materially impair the company’s core program and long-term value proposition.
Cardiff Oncology News
XE7C FAQ
What was Cardiff Oncology, Inc.’s price range in the past 12 months?
Cardiff Oncology, Inc. lowest stock price was €1.13 and its highest was €3.76 in the past 12 months.
What is Cardiff Oncology, Inc.’s market cap?
Cardiff Oncology, Inc.’s market cap is €90.78M.
When is Cardiff Oncology, Inc.’s upcoming earnings report date?
Cardiff Oncology, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 45 days.
How were Cardiff Oncology, Inc.’s earnings last quarter?
Cardiff Oncology, Inc. released its earnings results on May 14, 2026. The company reported -€0.155 earnings per share for the quarter, missing the consensus estimate of -€0.116 by -€0.039.
Is Cardiff Oncology, Inc. overvalued?
According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued.
Does Cardiff Oncology, Inc. pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
What is Cardiff Oncology, Inc.’s EPS estimate?
Cardiff Oncology, Inc.’s EPS estimate is -0.1.
How many shares outstanding does Cardiff Oncology, Inc. have?
Cardiff Oncology, Inc. has 68,369,896 shares outstanding.
What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?
Cardiff Oncology, Inc. reported an EPS of -€0.155 in its last earnings report, missing expectations of -€0.116. Following the earnings report the stock price went up 5.704%.
Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?
Currently, no hedge funds are holding shares in DE:XE7C
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiff Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€5.19 (232.91% Upside)
€5.19 (232.91% Upside)
Blogger Sentiment
Bullish
DE:XE7C Sentiment 70%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.36%
12-Months-Change
Fundamentals
Return on Equity
-95.51%
Trailing 12-Months
Asset Growth
-42.02%
Trailing 12-Months
Company Description
Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage biotechnology firm located in San Diego, California, is dedicated to developing innovative medical treatments for cancer patients. Its lead therapeutic agent is onvansertib, an oral and selective inhibitor of Polo-like Kinase 1 (PLK1), which is being investigated for various anti-cancer applications, including clinical trials for metastatic colorectal cancer. The company's pipeline further includes CY140, an inhibitor targeting PLK1, PLK2, and PLK3, currently progressing through Phase 1/2 studies for both solid tumors and leukemias. Additionally, Cardiff Oncology is advancing TROV-054 in Phase 1b/2 trials, exploring its combination with FOLFIRI and bevacizumab, and TROV-053 in a Phase II clinical trial, where it is being assessed alongside Zytiga for metastatic castration-resistant prostate cancer. Established in 1999, the company, which primarily supplies its pharmaceutical innovations to manufacturers, was originally known as Trovagene, Inc. It officially rebranded to Cardiff Oncology, Inc. in May 2012.
XE7C Stock 12 Month Forecast
Average Price Target
€5.19
▲(232.91% Upside)
Technical Analysis
Oncolytics Biotech
―
―
Avalo Therapeutics
―
Greenwich LifeSciences
―
Molecular Partners
―
Pyxis Oncology
―
Options Prices
Currently, No data available
---